Target expression details
| Target's General Information | |||||
|---|---|---|---|---|---|
| Target ID | T72038 | ||||
| Target Name | Galectin-3 (LGALS3) | ||||
| Synonyms | Mac-2 antigen; MAC2; Lectin L-29; Laminin-binding protein; L-31; IgE-binding protein; Galactoside-binding protein; Galactose-specific lectin 3; Gal-3; GALBP; Carbohydrate-binding protein 35; Carbohydrate binding protein 35; CBP 35; Beta-galactoside-binding protein LGALS3; 35 kDa lectin | ||||
| Target Type | Clinical trial | ||||
| Gene Name | LGALS3 | ||||
| UniProt ID | LEG3_HUMAN | ||||
| Target's Expression Profile in Disease Related Tissue between Patients and Normal People | |||||
| Disease | Melanoma | ||||
| Example drug | GR-MD-02 | Phase 2 | [1], [2] | ||
| Tissue | Skin | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.05 Z-score: -0.08 P-value: 4.24E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02421094) Clinical Study for Non-Invasive Imaging Methods for GR-MD-02 for Treatment of Liver Fibrosis. U.S. National Institutes of Health. | ||||
| REF 2 | NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.